	US 12,410,211 B2
	V1A receptor partial agonist and method of use
Han Jiang, Burlingame, CA (US); Yao Yao, Seattle, WA (US); Gerardo M. Castillo, Bothell, WA (US); Akiko Nishimoto-Ashfield, Seattle, WA (US); Christian Ventocilla, San Francisco, CA (US); and Elijah Bolotin, Bothell, WA (US)
Assigned to PHARMAIN CORPORATION, Bothell, WA (US)
Appl. No. 18/013,389
Filed by PharmaIN Corporation, Bothell, WA (US)
PCT Filed Jul. 16, 2021, PCT No. PCT/US2021/041998 § 371(c)(1), (2) Date Dec. 28, 2022, PCT Pub. No. WO2022/016064, PCT Pub. Date Jan. 20, 2022.
Claims priority of provisional application 63/053,340, filed on Jul. 17, 2020.
Prior Publication US 2023/0248800 A1, Aug. 10, 2023
Int. Cl. C07K 7/16 (2006.01); A61K 31/55 (2006.01); A61P 7/10 (2006.01); A61P 9/12 (2006.01)

CPC C07K 7/16 (2013.01) [A61K 31/55 (2013.01); A61P 7/10 (2018.01); A61P 9/12 (2018.01)]

25 Claims

1. A peptide comprising Formula (A):

	(A)
	[Mpa-Tyr-Phe-Z-Asn-Cys-Pro-B(X)_a-Gly-NH₂],

or a pharmaceutically effective salt thereof,

wherein:

the Mpa and Cys residues are covalently connected with a disulfide bond;

Z is Hgn;

B is L-Lys, D-Lys, L-Dap, D-Dap, L-Orn, D-Orn, L-Dab, or D-Dab;

X is independently selected at each occurrence from Gly, L-Ala, D-Ala, L-Lys,

D-Lys, L-Orn, D-Orn, L-Glu, D-Glu, L-Asp, and D-Asp; and

a is an integer from 0 to 9.